AIM
TARA icon

Acrospire Investment Management’s Protara Therapeutics TARA Stock Holding History

Acrospire Investment Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12
Closed -$1K – 2523
2017
Q1 		$1K Buy
+12
New +$897 ﹤0.01% 2155

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acrospire Investment Management's TARA Position: Q2 2017 in Review

Acrospire Investment Management sold out of Protara Therapeutics (TARA) in Q2 2017, closing a stake of 12 shares — an estimated $1K sold.

Acrospire Investment Management first reported a position in TARA in Q1 2017 and held it in 1 quarter. The position peaked at $1K in Q1 2017. 28 funds tracked by Wall St. Rank hold TARA as of Q2 2017.

  • Acrospire Investment Management reported no remaining Protara Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 12 Protara Therapeutics shares in Q2 2017, an estimated $1K.
  • Acrospire Investment Management first reported a position in Protara Therapeutics in Q1 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Protara Therapeutics position peaked at $1K in Q1 2017.
  • 28 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.